BMY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 30, 2026Sponsor estimate | NCT03989414A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination...Celgene · Multiple Myeloma | BMYLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT04735978Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursReplimune, Inc. · Advanced Solid Tumor | REPLLeadBMYCollaborator | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT05688475A Rollover Study of CC-122Bristol-Myers Squibb · Non-Hodgkin Lymphoma | BMYLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT03989414A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination...Celgene · Multiple MyelomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT04735978Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursReplimune, Inc. · Advanced Solid TumorActive, not recruitingREPLLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1NCT05688475A Rollover Study of CC-122Bristol-Myers Squibb · Non-Hodgkin LymphomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT03610711REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other...Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Gastroesophageal CancerActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT04900818Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsI-Mab Biopharma US Limited · Solid TumorRecruitingNBPLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT04989946Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed...University of Wisconsin, Madison · Prostate CancerActive, not recruitingREGNCollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 5, 2026Sponsor estimatePhase 1NCT07777133A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy...Bristol-Myers Squibb · Healthy Female ParticipantsRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimatePhase 1NCT07763418A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal...Bristol-Myers Squibb · Kidney Failure, ChronicRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 1NCT07226817A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult ParticipantsBristol-Myers Squibb · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 19, 2026Sponsor estimatePhase 1NCT07837115A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of...Celgene · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2026Sponsor estimatePhase 1NCT07655518A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult...Bristol-Myers Squibb · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 1NCT04299113Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent RhabdomyosarcomaJonsson Comprehensive Cancer Center · RhabdomyosarcomaActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 1NCT04606316Surgical Nivolumab And Ipilimumab For Recurrent GBMGilbert Youssef · GlioblastomaActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT06209619CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaNathan Denlinger · B-Cell Non-Hodgkin Lymphoma-RecurrentRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 2027Sponsor estimatePhase 1/Phase 2NCT03033914A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Memorial Sloan Kettering Cancer Center · Hodgkin LymphomaActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1/Phase 2NCT03465592Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · SarcomaRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT06026410KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsKura Oncology, Inc. · Solid Tumors With HRAS AlterationsRecruitingKURALeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2027Sponsor estimatePhase 1/Phase 2NCT06481306A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseBristol-Myers Squibb · Anemia, Sickle CellRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2027Sponsor estimatePhase 1NCT07077434A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid TumorsBristol-Myers Squibb · Advanced Solid TumorsRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD · Atypical Teratoid Rhabdoid Tumor | BMYCollaborator | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Feb 15, 2027Sponsor estimate | NCT02886065A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MMMassachusetts General Hospital · Smoldering Multiple Myeloma | BMYCollaborator | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 1/Phase 2NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD · Atypical Teratoid Rhabdoid TumorActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2027Sponsor estimatePhase 1NCT02886065A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MMMassachusetts General Hospital · Smoldering Multiple MyelomaActive, not recruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.